john kuruvilla: pembrolizumab in relapsed/refractory classic hodgkin lymphoma
Published 4 years ago • 741 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
0:59
dr. kuruvilla on the treatment landscape in relapsed/refractory hodgkin lymphoma
-
1:24
dr. kuruvilla on the safety of pembrolizumab in classical hodgkin lymphoma
-
4:10
pembrolizumab vs brentuximab vedotin in relapsed or refractory classic hodkin lymphoma
-
0:58
dr. kuruvilla on the broad utility of pembrolizumab in hodgkin lymphoma
-
5:01
relapsed & refractory classic hodgkin lymphoma
-
1:15
pembrolizumab plus vorinostat in patients with hodgkin lymphoma refractory to prior pd-1 blockade
-
3:43
keynote-204: pembrolizumab versus brentuximab vedotin r/r classic hodgkin lymphoma
-
1:09:24
update on immunotherapy in the treatment of lymphoma | lrf webinars
-
6:32
relapse of low-grade non-hodgkin lymphoma
-
20:27
pharmacological chaperones for cellular prion protein by emiliano biasini
-
1:28
concurrent pembrolizumab and chemotherapy in classical hodgkin lymphoma
-
1:25
keynote-204: pembrolizumab vs brentuximab vedotin in r/r chl
-
3:51
phase iii keynote-204: does prior therapy impact outcomes in r/r chl?
-
0:35
nivolumab and pembrolizumab and the current treatment landscape for hodgkin lymphoma
-
3:07
keynote-204 in r/r classical hodgkin lymphoma
-
1:41
pembrolizumab improves pfs in hodgkin lymphoma compared with brentuximab vedotin
-
0:49
pembrolizumab combined with favezelimab for heavily pretreated classical hodgkin lymphoma
-
1:36
possibilities for the use of pembrolizumab in lymphoma treatment
-
51:26
lymphoma treatment options john kuruvilla
-
1:14
pd-l1 inhibitors in r/r hodgkin lymphoma
-
1:23
cch-qc montréal 2017: dr. john kuruvilla - hodgkin's lymphoma
-
1:43
keynote-667: pembrolizumab for children and young adults with classical hodgkin lymphoma